Browsing Tag

DLL3

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology…

Kemal Pasha May 2, 2022

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply…

Health

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

Jason Junior Jun 5, 2021

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell…